drugset / Trial / NCT04155580
A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)
Non-randomizedSequentialOpen-labelTreatment
Summary
To evaluate the safety, pharmacokinetics (PK), and efficacy of ASTX660 when given alone and in combination with ASTX727 in participants with relapsed/refractory (R/R) acute myeloid leukemia (AML). The duration of the study is expected to be approximately 30 months.
Timeline
- Start
- 2020-06-12
- Primary completion
- 2022-01-14
- Completion
- 2022-01-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ASTX660 | Small molecule | — | Oral |
| Subject | Cedazuridine | Small molecule | — | Oral |
| Subject | Decitabine | Small molecule | — | Oral |